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INTRODUCTION
Sertoli–Leydig cell tumor (SLCT) is a type of ovarian sex
cord-stromal tumors [1] which occurs most frequently in the
second and third decades. They are generally low-grade malig-
nancies, and less than 20% become malignant [1,2]. We present
two unusual high-risk cases where there was evidence of genetic
predisposition (metachronous tumor discovered at relapse in one
case, the other was a second primary tumor in a survivor of Wilms
tumor). As both cases fell into a category of expected event free
survival (EFS) of <50% [3], we wished to utilize maintenance
antitumor therapy to cover the highest risk period of relapse [4].
We chose a long acting GnRH analog (leuprorelin) to suppress
any residual tumor cell proliferation.
PATIENTS AND RESULTS
Case 1
A 12-year old female was diagnosed with right ovarian mass after
presentation with a 7-month history of abdominal distension. Tumor
markers were normal except for moderately raised AFP (Alfa
fetoprotein-35 ku/L) and inhibin A and B (10.2 and 108.0 pg/ml,
respectively (Fig. 1A) measured postoperatively). The mass was
completely resected and histopathology revealed SLCT stage 1A.
Fourteen months later, a left ovarian and a right para-aortic
lymph node mass were detected on routine ultrasound scan. Tu-
mor markers were normal except for raised inhibin B 294 pg/ml
(normal range <8–196 pg/ml, Fig. 1A). The lymph node biopsy
conﬁrmed the recurrence of SLCT. Chemotherapy consisting of
cisplatin, ifosfamide, and etoposide (PIE) was administered as per
the schedule used by the German Pediatric Oncology Group for
germ cell tumor [5].
Following four courses of chemotherapy, the para-aortic
lymph node and left ovary were resected. Microscopically, the
lymph node metastases showed predominant Sertoli cell features,
consistent with metastasis from the original right ovarian tumor
(Fig. 2C). By contrast, the left ovarian tumor showed groups of
deﬁnite Leydig cells (Fig. 2A and B) with a sheet like structure
and was very different histologically from the original right-sided
ovarian tumor. For this reason, the left ovarian tumor was felt to
represent a metachronous contra lateral new primary tumor.
Due to the poor survival despite intensive therapy reported in
the German series [4], we consolidated this remission with high
dose therapy (carboplatin, etoposide, and melphalan) with autolo-
gous stem cell rescue and radiotherapy (54 Gy) to the para-aortic
lymph nodal area. On recovery, she commenced the GnRH analog
leuprorelin acetate for 2 years (leuprorelin 3.75 mg, intramuscular
(IM), three weekly for three cycles, followed by a longer acting
form (11.25 mg IM injection every 9 weeks). Efﬁcacy of suppres-
sion of LH/FSH was monitored regularly. The treatment was well
tolerated. Six months after stopping GnRH analogs, hormonal
replacement therapy with estradiol was introduced. She remains
well 6 years from time of relapse and 3 years from end of
leuprorelin treatment.
Case 2
A 12-year old female diagnosed with large left ovarian mass
after presentation with history of menorrhagia and of an abdom-
inal mass. She was previously treated at the age of 8 years for a
Wilms tumor. She also has cystic multinodular goiter. Further
investigations showed no evidence of metastases. Preoperative
AFP was raised (191 ku/L) and inhibin B was in the higher
range (81.4 pg/ml) when ﬁrst measured postoperatively.
She proceeded to complete resection of the left ovary and
complete macroscopic excision of a small nodule noted on the
right ovary during the surgery. Histopathology (Fig. 2D and E) of
both tumor and the nodule showed intermediate to poorly differ-
entiated SLCT (stage 1C).
Postoperative MRI showed a right ovarian mass. Following
two courses of PIE chemotherapy, the right ovary was completely
removed and histopathology (Fig. 2F) showed a SLCT with inter-
mediate differentiation, stage 1C. She commenced leuprorelin
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acetate according to the same schedule as case 1 after completing
four courses of chemotherapy. The interval between injections
was reduced to 6 weeks in order to keep LH and FSH levels fully
suppressed. She completed 2 years of this therapy and hormone
replacement therapy was commenced similar to case 1. She
remains in complete remission at 4 years from diagnosis and
30 months after completion of GnRH therapy. The one abnormal
inhibin A level measured during follow up was ascribed to a
laboratory error and subsequent levels were normal (Fig. 1B).
Detection of GnRH Receptors
The receptor binding studies were conducted on frozen tumor
from case 1 [6]. Membranes from a HEK293 cell line stably
expressing the GnRH receptor (SCL60) and rat pituitary were
used as positive controls and liver membranes as negative control.
Two separate samples of Case 1 tumor showed speciﬁc binding
of radiolabelled GnRH analog as did SCL60 and pituitary
(Fig. 1C and D).
DISCUSSION
There are few data in the literature on risk-adapted therapeu-
tic strategies in ovarian sex cord stromal cell tumors in children.
Schneider et al. [4] described 54 cases documented prospective-
ly and deﬁned risk groups with respect to stage; completeness
of resection; histologic appearance, such as differentiation and
proliferative activity of the tumor. Surgery remains the mainstay
of initial management. Cisplatin based chemotherapy constitutes
an important role as adjuvant therapy for those patients with
SLCT stage I, poorly differentiated and those containing heter-
ologous elements.
In 1975, Stadel [7] proposed the ‘‘gonadotropin theory,’’ hy-
pothesizing that exposure to high gonadotropin levels favor ma-
lignant transformation. SLCTs express receptors for follicle
stimulating hormone (FSH) which has been shown to support
the growth of granulosa cell tumors in nude mice [8]. GnRH
analog therapy at high doses can act to suppress the receptor
activity and has been suggested as treatment for progressive ovar-
ian tumors that have failed to respond to chemoradiation [9]. The
apparent efﬁcacy of GnRH analog in our SLCT patients which
lowered gonadotropins may support this theory. There may have
also been direct antiproliferative effects as described in a number
of reproductive tissue cancers, including ovarian cancer [10–15].
Although there are case reports about the use of GnRH analog for
SLCTs of the ovary in adults [16], no data have been reported in
children. Whilst we could not demonstrate tumor response in the
absence of measurable disease or raised tumor markers, we are
encouraged by the duration of clinical remission in both patients
and their lack of problems on introduction of hormone replace-
ment therapy.
Fig. 1. Case 1 inhibin A and B levels (A) and case 2 AFP, inhibin A and B levels (B) [normal range—inhibin A in premenopausal women
varies with the cycle <7–69 pg/ml and inhibin B in girls aged 11–12 years as per Women and Infants Hospital, Rhode Island, US is —<10–
186 pg/mol. Alfa-fetoprotein (AFP) is <10 ku/L]. GnRH receptor study on the case 1 specimen (C) [cell line SCL 60 expressing GnRH
receptor, pituitary membranes as positive control and liver membranes as a negative control. The second column of each is the non-speciﬁc
binding (106 M ligand). Both tumor specimen A and B had speciﬁc binding]. Dose–response binding curve of cell membranes of case 1
specimen demonstrating high afﬁnity binding sites suggestive of GnRH receptors (D).
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Recent advances in the understanding of the genetics of
SLCTs have provided insight into the unusual clinical phenotype
in the two cases presented here. Both were included in a study of
the rare pleuropulmonary blastoma syndrome of which SLCTs
have recently been shown to form part of the spectrum [17]. This
syndrome is due to constitutional heterozygous mutations in the
DICER1 gene, the master regulator of micro RNA production.
Both cases presented had constitutional DICER1 mutations. DIC-
ER1 mutations can cause a range of phenotypes from asymptom-
atic to various tumors such as cystic nephroma, pleuropulmonary
blastoma, thyroid cysts, SLCTs, and Wilms tumor. Case 2 also
has thyroid cysts, now recognized as part of the DICER1 syn-
drome [17].
In conclusion, the prolonged remission in two cases presented
here suggests that GnRH analogs may have a therapeutic role
in high risk SLCTs. While we do not have direct evidence for
the efﬁcacy of GnRH analogs with potential inﬂuence of high
dose therapy and stem cell rescue on case 1, our ﬁndings set the
scene for further studies for maintenance therapy using GnRH
analogs in SLCTs.
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Fig. 2. Case 1 left side tumor [H&E 200] showing solid nests, cords of Sertoli cells with clusters of Leydig cells (A) and its inhibin staining
(B) [inhibin 400]. Case1 para aortic lymph node [H&E 200] deposit [14 months later] predominant Sertoli cell features, with small tubules
and cords in a hyalinised background and occasional incorporated larger ‘‘heterologous’’ glandular elements with retiform areas (C) [consistent
with metastasis from the original right ovarian tumor that had shown similar features]. Case 2 left side tumor [H&E 100] cells with a partly
retiform arrangement in a loose stroma and intermingled clusters of Leydig cells (D) and its inhibin staining (E) [inhibin 200]. Case 2 right
side tumor [H&E 200]-loose sheets of Sertoli cells and sparse interspersed Leydig cells (F).
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